论文部分内容阅读
目的:研究肾康注射液对维持性血液透析患者氧化应激及微炎症状态的影响。方法:选取我院肾内科行维持性血液透析的患者80例,按照随机数字表法分为治疗组和对照组各40例,对照组予调节血压、改善贫血等常规治疗,治疗组在对照组治疗基础上加用肾康注射液,比较两组患者治疗前后氧化应激水平、微炎症状态及药物不良反应发生情况。结果:对照组治疗前后MDA、SOD、A-TOC、CRP、IL-6、TNF-α水平均无明显变化(P>0.05);治疗组治疗后MDA、CRP、IL-6、TNF-α较治疗前明显降低,而SOD、T-AOC明显升高(P<0.05);和对照组比较,治疗组治疗后MDA、SOD、T-AOC、CRP、IL-6、TNF-α改善更加明显,差异有统计学意义(P<0.05);两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论:肾康注射液可降低维持性血液透析患者的微炎症反应水平,促进氧化和抗氧化之间的平衡,临床疗效确切,安全性高。
Objective: To investigate the effects of Shenkang injection on oxidative stress and microinflammatory state in maintenance hemodialysis patients. Methods: Eighty patients with maintenance hemodialysis in our hospital were divided into treatment group (n = 40) and control group (n = 40) according to random number table. The control group was given conventional therapy such as blood pressure regulation and anemia improvement. In the control group On the basis of treatment, Shenkang injection was used to compare the levels of oxidative stress, microinflammation and adverse drug reactions in both groups before and after treatment. Results: The levels of MDA, SOD, A-TOC, CRP, IL-6 and TNF-α did not change significantly in the control group before and after treatment (P> 0.05) (P <0.05). Compared with the control group, the improvement of MDA, SOD, T-AOC, CRP, IL-6 and TNF-α in the treatment group was more obvious after treatment, The difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P> 0.05). Conclusion: Shenkang injection can reduce the level of micro-inflammation in maintenance hemodialysis patients and promote the balance between oxidation and anti-oxidation. The clinical effect is definite and safe.